The newly-developed Reveal Q+ MAX test is likely to fortify Neogen's (NEOG) presence in the global food allergen testing market.
The latest offering in Intersect ENT's (XENT) SINUVA portfolio is specific J code - J7401.
Per Walgreens (WBA), its alliance with Kroger will lead to supply chain efficiencies, capitalizing on their joint resources.
Investors can retain Quest Diagnostics (DGX) stock in their portfolio, thanks to solid prospects.
Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.
This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.
NUVA vs. HAE: Which Stock Is the Better Value Option?
Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.
Amedisys' (AMED) impressive performance in the newly-unveiled Personal Care segment is appreciative.
Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.
NuVasive (NUVA) is optimistic about maintaining the momentum on several positive developments.
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.
These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.
Within NuVasive's (NUVA) U.S. Spinal Hardware business, a strong uptick in case volume and tangible growth in the XLIF and ALIF franchises are major upsides.
Under the contract, ArcherDX will develop IVD tests that will run on Illumina's (ILMN) NextSeq 550Dx System.
Haemonetics (HAE) expands the transfusion management portfolio with SafeTrace Tx, the latest in its transfusion management software product line.
The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.